Add like
Add dislike
Add to saved papers

Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents.

Sixteen patients (ten women and six men, ranging in age from 20 to 67 years) with active bilateral posterior uveitis of noninfectious origin were treated with cyclosporin A, a specific anti-T-cell medication. All had previously received systemic corticosteroids or cytotoxic agents or both and had responded poorly or had intolerable side effects. Fifteen of 16 patients had positive responses to oral cyclosporin A therapy (initially 10 mg/kg of body weight/day), measured by a decrease in inflammatory activity, with a concomitant improvement in visual acuity in most patients. Fluorescein angiographic findings varied considerably with some patients showing an improvement with continued cystoid macular edema. Renal toxicity occurred in five patients, but renal function reverted toward normal with a decrease in cyclosporin A dosage.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app